Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcus Biosciences Inc
(NY:
RCUS
)
14.28
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
14.28
Bid (Size)
14.27 (1)
Ask (Size)
16.08 (1)
Prev. Close
14.28
Today's Range
14.28 - 14.28
52wk Range
13.49 - 20.31
Shares Outstanding
91,500,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
November 19, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
November 12, 2024
From
Arcus Biosciences
Via
Business Wire
Performance
YTD
-27.44%
-27.44%
1 Month
-15.00%
-15.00%
3 Month
-19.28%
-19.28%
6 Month
-12.29%
-12.29%
1 Year
+2.96%
+2.96%
More News
Read More
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
November 06, 2024
From
Arcus Biosciences
Via
Business Wire
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts
November 06, 2024
Via
Benzinga
Unveiling 5 Analyst Insights On Arcus Biosciences
October 21, 2024
Via
Benzinga
Where Arcus Biosciences Stands With Analysts
October 21, 2024
Via
Benzinga
Demystifying Arcus Biosciences: Insights From 4 Analyst Reviews
October 03, 2024
Via
Benzinga
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
November 05, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
October 30, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
October 24, 2024
From
Arcus Biosciences
Via
Business Wire
Breaking Down Arcus Biosciences: 4 Analysts Share Their Views
August 09, 2024
Via
Benzinga
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
October 24, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
October 22, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
October 09, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
October 09, 2024
From
Arcus Biosciences
Via
Business Wire
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
October 08, 2024
Via
Benzinga
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
October 02, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
September 24, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
September 10, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
August 27, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
August 26, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
August 21, 2024
From
Arcus Biosciences
Via
Business Wire
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update
August 08, 2024
From
Arcus Biosciences
Via
Business Wire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
